CSF3 and acute myeloid leukemia: Indeed, the so-called CAG regimen, composed by low-dose cytarabine, aclarubicin, and recombinant granulocyte-colony stimulating factor (G-CSF), is been widely used in China and Japan for the treatment of AML.49,50 A single-center retrospective study compared the efficacy of CAG to other salvage chemotherapies in relapsed/refractory acute myeloid leukemia (r/rAML) patients to discover that the aclarubicin-containing CAG regimen assured a notable 23% increase in 5-year overall survival compared to other intensive chemotherapies.47